BioSight
Companies
PALVELLA THERAPEUTICS, INC. logo

PVLA

NASDAQWAYNE, PA
PALVELLA THERAPEUTICS, INC.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on rare disease and ophthalmology, with lead programs QTORIN rapamycin and QTORIN pitavastatin representing its primary development efforts. The company was formed through a merger between Pieris Pharmaceuticals, Inc. and Legacy Palvella Therapeutics, Inc., completed in December 2024, combining their therapeutic platforms and pipeline assets.

Price history not yet available for PVLA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar